Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy. |
| |
| Authors: | Lutz Liefeldt Martin Buhl Britta Schweickert Elisabeth Engelmann Orhan Sezer Peter Laschinski Lothar Preuschof Hans-H Neumayer |
| |
| Affiliation: | Department of Nephrology, Charité, Humboldt-University Berlin, Germany. lutz.liefeldt@charite.de |
| |
| Abstract: | | Introduction | Anaemia is a frequent problem after renal transplantation, whichmay appear as hypo-regenerative anaemia (due to myelotoxic drugsor infectious agents and/or poor graft function) or hyper-regenerativeanaemia (haemolysis or bleeding). It, therefore, seems reasonableto distinguish between different underlying causes of anaemiaaccording to reticulocyte counts. One of the presumably rather rare infectious agents causingtransient hypo-regenerative anaemia is the human parvovirusB19 (HPV B19) that was discovered in human blood 25 years ago[1] and was found to be the cause of fifth diseasein children in the 1980s
| |
| Keywords: | eradication immunosuppression i.v. immunoglobulin parvovirus B19 pure red cell anaemia renal transplantation |
| 本文献已被 Oxford 等数据库收录！ |
|
